EMA publishes reflection paper on issues regarding the parenteral administration of coated nanomedicines.
The European Medicines Agency (EMA) has published a reflection paper on general issues regarding the development of coated nanomedicines. The paper addresses issues that may arise in the development of nanomedicines that have a coating, including the effect of the coating on stability and possible interactions with other molecules.
The reflection paper is one in a series of four guidance documents discussing nanomedicines. EMA’s Committee for Medicinal Products for Human Use began developing guidance on the development of new nanomedicines and nanosimilars in 2011.
